Note sull'episodio
This week's sweep is organized around one theme that turned up in almost every item — the gap between moving a number and changing an outcome. It opens with a correction to the lipoprotein(a) episode from the seventeenth: pelacarsen lowered Lp(a) substantially in a trial of more than eight thousand patients and did not reduce cardiovascular events, and ziltivekimab did the same thing with hsCRP. It then covers the new VA/DoD tobacco treatment guideline and its strong recommendations for varenicline over other monotherapy and combination over single-agent nicotine replacement, paired with a trial mailing varenicline directly to smokers; a national survey showing alcohol use falling overall while heavy drinking among adults fifty to sixty-four rose more than a third; coronary calcium added to PREVENT, where the reclassification arithmetic runs the wrong way; anticoagulation for intermediate-risk atrial fibrillation in a Korean trial; the oral PCSK9 inhibitor enlicitide; and the American Cancer Society's updated position on blood-based colorectal cancer screening.